Statute Details
- Title: Health Products (Exemptions) Order 2016
- Act Code: HPA2007-S536-2016
- Legislation Type: Subsidiary legislation (SL)
- Authorising Act: Health Products Act (Cap. 122D), section 70
- Commencement: 1 November 2016
- Current Status: Current version as at 27 Mar 2026
- Enacting Authority: Health Sciences Authority (HSA)
- Key Provisions:
- Section 1: Citation and commencement
- Section 2: Definitions
- Section 3: Exemptions set out in Schedules (therapeutic products, medical devices, CTGT products)
- Section 4: Revocation of earlier exemption orders
- Schedules:
- First Schedule: Exemptions relating to therapeutic products
- Second Schedule: Exemptions relating to medical devices
- Third Schedule: Exemptions relating to CTGT products
- Notable Amendments (timeline highlights): Amended by S 321/2018, S 110/2021 (effective 1 Mar 2021), S 435/2023 (effective 31 Dec 2021), and S 804/2023 (effective 18 Dec 2023)
What Is This Legislation About?
The Health Products (Exemptions) Order 2016 is a Singapore legal instrument made under the Health Products Act. Its central function is to specify when certain “health products” are exempt from regulatory requirements under the Health Products Act and its related regulations.
In practical terms, the Order does not create a general licensing regime by itself. Instead, it acts as a “gatekeeper” document: it identifies categories of therapeutic products, medical devices, and cell, tissue and gene therapy (CTGT) products that are exempt from specified controls. This matters because the Health Products framework is compliance-heavy—requiring approvals, registrations, or other regulatory steps depending on the product category and intended use. Exemptions reduce the compliance burden for products that pose lower regulatory risk or fall within defined circumstances.
The Order is structured around the three major product groupings recognised in the Health Products Act framework: therapeutic products, medical devices, and CTGT products. It achieves this by defining key terms and then directing readers to the relevant schedules where the exemptions are listed in detail. For practitioners, the schedules are the “work product” of the Order: they determine whether a particular product or activity falls within an exemption and therefore whether regulatory steps can be avoided.
What Are the Key Provisions?
Section 1 (Citation and commencement) provides the legal identity and start date. The Order is cited as the Health Products (Exemptions) Order 2016 and comes into operation on 1 November 2016. For compliance planning, this date is important when assessing whether a product’s regulatory pathway is governed by the 2016 Order or earlier exemption instruments.
Section 2 (Definitions) sets the interpretive foundation. The definitions are tightly linked to the categorisation approach in the Health Products Act. In particular, the Order defines:
- “therapeutic product” as a health product categorised as such in the First Schedule to the Act;
- “medical device” as a health product categorised as such in the First Schedule to the Act;
- “CTGT product” as a health product categorised as a cell, tissue or gene therapy product in the First Schedule to the Act;
- “CTGT Products Regulations” as the Health Products (Cell, Tissue and Gene Therapy Products) Regulations 2021 (G.N. No. S 104/2021); and
- “Therapeutic Products Regulations” as the Health Products (Therapeutic Products) Regulations 2016 (G.N. No. S 329/2016).
These definitions are not merely academic. They ensure that the exemption schedules are read consistently with the Act’s product classification scheme. A common legal issue in health product regulation is misclassification—whether something is a therapeutic product versus a medical device, or whether a product is a CTGT product. Section 2 helps anchor the analysis to the Act’s categorisation.
Section 3 (Exemptions) is the operative provision that tells you where to look. It provides that:
- Section 3(1): exemptions relating to therapeutic products are set out in the First Schedule;
- Section 3(2): exemptions relating to medical devices are set out in the Second Schedule;
- Section 3(3): exemptions relating to CTGT products are set out in the Third Schedule.
Notably, the CTGT-related schedule was introduced or expanded by later amendments (as indicated by the reference to S 110/2021 effective 1 March 2021). For practitioners, this is a reminder that the exemption landscape evolves as new regulatory categories (such as CTGT) are brought into the statutory framework.
Section 4 (Revocation) revokes earlier exemption orders relating to medical devices: Health Products (Medical Devices) (Exemption) Order 2012 and Health Products (Medical Devices) (Exemption No. 2) Order 2012. The legal significance of revocation is straightforward but critical: once revoked, the earlier orders no longer govern. If a practitioner is assessing historical compliance (e.g., for audits, enforcement responses, or due diligence), it is essential to determine which exemption order was in force at the relevant time.
Schedules (the practical core) are referenced but not reproduced in the extract provided. However, the legal architecture is clear: the First Schedule lists therapeutic product exemptions; the Second Schedule lists medical device exemptions; and the Third Schedule lists CTGT product exemptions. In most exemption regimes, schedules typically specify the precise regulatory requirement from which the product/activity is exempt (for example, exemptions from registration, licensing, or approval), and may include conditions such as intended use, distribution channels, quantities, or documentation requirements. Practitioners should therefore treat the schedules as the authoritative source for whether an exemption applies.
How Is This Legislation Structured?
The Order is concise and follows a standard subsidiary-legislation format:
- Part/Sections: It contains four sections only (Sections 1 to 4).
- Definitions: Section 2 defines the key product categories and cross-references relevant regulations.
- Exemptions: Section 3 is a routing provision directing readers to the schedules.
- Revocation: Section 4 removes earlier medical device exemption orders.
- Schedules: Three schedules provide the detailed exemption lists:
- First Schedule — therapeutic products
- Second Schedule — medical devices
- Third Schedule — CTGT products
From a legal research perspective, the structure means that the “analysis work” is largely performed by reading the schedules in conjunction with the Health Products Act and the relevant product-specific regulations. The Order tells you what is exempt; the Act and regulations tell you from what and under what conditions.
Who Does This Legislation Apply To?
The Order applies to persons and entities dealing with health products in Singapore—particularly those who would otherwise need to comply with regulatory requirements under the Health Products Act and its product-specific regulations. While the Order itself is framed as an exemption instrument, the practical effect is to determine the compliance obligations of manufacturers, importers, distributors, and other regulated stakeholders who place therapeutic products, medical devices, or CTGT products on the market or otherwise engage in regulated activities.
Because the exemptions are category-specific (therapeutic products, medical devices, CTGT products), applicability depends on (i) the correct regulatory classification of the product and (ii) whether the product/activity fits within the specific exemption terms in the relevant schedule. Misclassification or failure to satisfy exemption conditions can result in the product being treated as non-exempt, triggering the full regulatory pathway.
Why Is This Legislation Important?
The Health Products (Exemptions) Order 2016 is important because exemptions are often the difference between a feasible market entry timeline and a prolonged regulatory process. For practitioners advising clients—whether in regulatory strategy, product launch planning, or enforcement responses—the Order provides the legal basis to argue that certain products or activities are outside the scope of specific regulatory requirements.
From an enforcement and risk-management standpoint, exemptions also create legal “pressure points.” If a company claims an exemption but cannot substantiate the factual basis (e.g., intended use, product classification, or compliance with any conditions), the exemption may be challenged. In such scenarios, the Order becomes central evidence in determining whether the regulatory authority had grounds to treat the activity as non-exempt.
Finally, the Order’s amendment history underscores that exemption regimes are dynamic. The introduction of CTGT exemptions (as reflected by later amendments effective 1 March 2021) illustrates how regulatory categories expand over time. Practitioners should therefore verify the current version (and, where relevant, the version in force at the time of the regulated conduct) rather than relying on older exemption lists.
Related Legislation
- Health Products Act (Cap. 122D) — in particular, section 70 (power to make this Order) and the Act’s product categorisation framework
- Health Products (Therapeutic Products) Regulations 2016 (G.N. No. S 329/2016)
- Health Products (Cell, Tissue and Gene Therapy Products) Regulations 2021 (G.N. No. S 104/2021)
- Health Products (Medical Devices) (Exemption) Order 2012 (revoked)
- Health Products (Medical Devices) (Exemption No. 2) Order 2012 (revoked)
Source Documents
This article provides an overview of the Health Products (Exemptions) Order 2016 for legal research and educational purposes. It does not constitute legal advice. Readers should consult the official text for authoritative provisions.